Switzerland Archives

morphosys novartis muscle simb bimagrumab

News and Trends 27 Apr 2016

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 26 Apr 2016

Illumina is Suing over NGS Prenatal Screening… Again

Genoma is being sued by Illumina over four patents covering technology for prenatal testing, that uses NGS to diagnose fetal defects. After suing Oxford Nanopore over porin technology, Illumina is back to another contentious field – their patents for a type of non-invasive prenatal testing (NIPT). Illumina has filed a patent infringement suit in the Federal […]

April 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

saphetor ngs lausanne university hospital endocrine

News and Trends 22 Apr 2016

Swiss Biotech to Investigate rare Endocrine Disorders with NGS

Saphetor is developing genome-scale analysis of next generation sequencing (NGS) results – and will now ‘play’ with real data of Endocrine patients at the Lausanne University Hospital. Based in Lausanne’s EPFL Innovation Park (Switzerland), Saphetor was founded only in 2014 and completed a seed financing round this February, raising around €1M (1.2M CHF). This startup develops proprietary […]

April 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

aacr 2016 merus transgene debiopharma innate

News and Trends 21 Apr 2016

These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

The annual meeting of the American Association for Cancer Research (AACR) has just finished. From Europe, who made a splash with their results? The AACR annual meeting is the world’s biggest conference in Cancer research, and the must-attend event for Biotechs developing cancer therapies. The 2016 edition took place in New Orleans (US) from the […]

April 21, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 18 Apr 2016

Very promising Results for Resistant Lung Cancer

Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival. Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland). One of the hard-to-treat cancers that Ariad is targeting is […]

April 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

evolva us navy composite material synbio

News and Trends 14 Apr 2016

European Biotech teams up with US Navy to engineer Military Materials

Evolva will join the US Navy to make new materials with its biosynthetic molecules – which could make it into aircrafts and ships. Evolva is a Synthetic biology Biotech headquartered near Basel (Switzerland), but with offices and R&D also in Denmark. It has developed its yeast platform to produce high-value chemicals via fermentation. So far, […]

April 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 4 Apr 2016

Allergy Immunotherapy from Switzerland gets several Million in funding

Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies. Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT). This process of inducing tolerance to the allergen requires 3-5 […]

April 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

philipp hemme labiotech conference novartis sachs biotech markus goebel

News and Trends 29 Mar 2016

Interviewing the Managing Director of the $750M Venture Fund of Novartis

This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of the Novartis Venture Fund. He almost played at home as he is living few dozen of kilometres outside the city in the lovely Swiss countryside. Novartis Venture Fund originates, as its name can tell, from […]

March 29, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 24 Mar 2016

Endeavouring to Establish Europe’s Largest MedTech Fund

The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide! Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure […]

March 24, 2016 - 2 minutesmins - By Dani Bancroft

humabs influenza antibody infectious cellclone medimmune

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

roche immuno oncology blueprint medicines boston

News and Trends 18 Mar 2016

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline. Roche is a leader in cancer therapies, but its position is threatened by intense competition, not to mention its stakes in the biosimilar war and some bad results from advanced trials. However, it seems that this Big Pharma still […]

March 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

Illumina is Suing over NGS Prenatal Screening… Again

Swiss Biotech to Investigate rare Endocrine Disorders with NGS

These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

Very promising Results for Resistant Lung Cancer

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

European Biotech teams up with US Navy to engineer Military Materials

Allergy Immunotherapy from Switzerland gets several Million in funding

Interviewing the Managing Director of the $750M Venture Fund of Novartis

Endeavouring to Establish Europe’s Largest MedTech Fund

Novel Antibody for Influenza gets FDA Fast-Track Approval

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!